Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Apr;13(4):166-9.

[Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?]

[Article in Spanish]
A Martínez Yélamos  1 , M Huerta Villanueva, M Olivé Plana, J Montero Homs, J Serra Catafau, J A Martínez-Matos
Affiliations
  • PMID: 9608755
Comparative Study

[Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?]

[Article in Spanish]
A Martínez Yélamos et al. Neurologia. 1998 Apr.

Abstract

The aim of this study was to compare the efficacy of IgIV versus plasmapheresis in the treatment of Guillain-Barré syndrome. Twenty-four Guillain-Barré patients were treated either with IgIV (n = 17), or plasmapheresis (n = 7). Evolution during the first year after onset were assessed using the motor functional scale of Hughes and nerve conduction studies. IgIV treated patients had better functional recovery than the plasmapheresis group (p < 0.05) and shorter hospital stays (p < 0.05). These differences were significant from day 30 after treatment. Complications occurred in 14 patients: 9 (58%) in the IgIV group, and 5 (71%) in the patients treated with plasmapheresis. IgIV treated patients had better functional recovery scores and shorter hospital stays. There were no differences in the complication rates. Therefore we believe that IgIV is the treatment of choice for Guillain-Barré syndrome in our clinical setting.

PubMed Disclaimer

Publication types

Substances